Wuxi Biortus Biosciences Co., Ltd. (Biortus) and Shenzhen XtalPi Technology Co., Ltd. (XtalPi) reached a strategic partnership agreement on August 26, 2019. The partnership is to leverage the respective expertise in experimental structural biology and in quantum computing and artificial intelligence to better serve drug discovery in pharma and biotech industry. The partnership involves the joint development of structural biology technology platform, including method and software development for experiment automation, image processing, and data analysis, as well as the joint promotion in marketing and business development among respective customers. The partnership is intended to capitalize on the synergy of XtalPi’s AI capabilities and Biortus’s experimental platforms and to serve the broader customer bases.
About Wuxi Biortus Biosciences Co., Ltd.: Biortus is the world's first contract research organization (CRO) featuring both crystallography and cryo-electron microscopy (Cryo-EM) platforms. Biortus’s services cover protein production in multiple expression systems including bacteria, insect cells, and mammalian cells, structural biology using both X-ray crystallography and cryo-EM technologies, small molecular microED structural analysis, biochemical and cellular assays and compound screening, medicinal chemistry and synthetic process development.
About Shenzhen XtalPi Technology Co., Ltd.: XtalPi is a R&D technology platform company with quantum theory, artificial intelligence (AI) and cloud computing at its core. It combines cutting-edge quantum physics and quantum chemistry theory with artificial intelligence algorithms, drug experiment development technology, and cloud-based high-performance computing to enhance drug development efficiency and improve success rate. It has in-depth cooperation with top pharmaceutical companies to provide solid-state R&D services (salt/crystal screening and crystal structure prediction), drug design platforms (spot compound discovery, lead compound generation/optimization, etc.), and artificial intelligence services. It has provided drug R&D services to more than 40 top pharmaceutical companies from the United States, Europe, China and Japan, and assisted more than 500 R&D activities in more than 100 new drug pipelines. XtalPi is headquartered in Shenzhen and has branches in Beijing and Boston.